Clinical trial registry record

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 29, 2021.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02404506
Last registry update
September 29, 2021
Status
Terminated
Phase
Phase 2
Sponsor
Swiss Cancer Institute
Enrollment
78
Countries
Switzerland
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
78
Population
FEMALE · 70 Years
Duration
2015-08-17 to 2021-07-22
Intervention
Eribulin mesilate
Comparator
Not reported
Outcomes measured
Disease Control (DC) — 24 weeks; Time to treatment failure (TTF) — at treatment discontinuation (at the latest 5 years after registration); Objective response (OR) — at treatment discontinuation (at the latest 5 years after registration); Time to progression (TTP) — at time of progression, death or treatment discontinuation (at the latest 5 years after reg…; Overall survival (OS) — at time of death (at the latest 5 years after registration); Adverse events (AEs) — until 30 days after last dose of treatment and resolution of all related AEs thereafter (at the…; Patient reported neuropathy (PRO Form) and characterization of patients based on cancer-specific geriatric assessment (…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON